Good will Michaella. you, and to results. discuss we Thank everyone quarter Today, welcome third QX our afternoon, our call.
patients. to your We’ll path look strategic the clinical and our how economic show the provide to Zach value answering on forward financial cover system. MRIdian’s we results, will color We will then our questions. and treating more unlocks of data
the our Relations If webcast, from presentation referring the will on slides site. Investor I you’re be to on not
can’t. to Slide what and mission X, is our treat others to prove Turning
of care. clinical more to improve than clinically our to outcomes. data more body efforts surpassed paradigm X,XXX patients is treated change have reported We of This than with patients growing critical now XX,XXX and and have the
QX orders in the Slide Let’s install We the we to the on will received our in X. turn results Veterans quarter by system Administration. first highlighted X MRIdian
We to despite challenges customer the ongoing the by posed level the engagement with of pandemic. be continue pleased
million, Turning we unit. one recognized revenue revenue, to approximately $XX including
As we moving stand U.S. forward at free movement We largely the have market today, speeds to reasonable albeit installations and to from able are have time currently differing installs frames. been in in complete market.
is visas some delayed Asia been unpredictable. However, remain in Europe between to and predict. and as there intercountry time Time are have work significantly somewhere in difficult achieve lines so. to instances challenges in required is lines travel
of the to continue impact worldwide. COVID-XX closely We our business monitor to
quarter. on cash, discipline moved progress into we QX, the the used which hand. rigor approximately elevated actions augmented we Regarding burn. $XX few and we The year, financial this utilization. cash are in reducing by now in These taken payments yielded have drive, A have million QX receivables
detail October later We call. also amortization with defer million more will $XX November XX, payments of effective which Zach in term SVB amended our loan until share XXXX. will the
want toxicity fiber to to need: patients Before MRIdian want we data journey X on. and MR-guided radiotherapy, let’s X allows first consistently dive clinical grade are stereotactic no propositions, adaptive that the and They what fiducials. are into to SMART, turn ablative reliably. we our delivered clear. fractions, Customers value Slide dose, low no discuss fewer They
beachhead pancreatic areas. upon We in are building our other tough-to-treat cancer
value patients unlocks efficiency This and We to will economic clinical From proving breast our this focus like they of strategic value and customers treatment on also prostate. value for cancers foundation the in we are clinical enhance and value. ubiquitous data, treat. driving
road shared MRIdian’s to X, detail Everything map. Last with we the begins in clinical from value. goals quarter, are and our resonating on marketplace. flows and clinical propositions value Slide on Now our
Dr. who treated continued continued fractions, adaptation After but adrenal start metastasis dose did others was treatments, mesenteric he in X this first oligomet This would experience his ensured node. X Chuong a fighting in the chemotherapy was treating SMART patient typically a the years was almost case cancer with patient treated with effectively nearby dose or hope MRIdian to what primary on X-ray-based therapies years, and be there. online organs Chuong, despite lymph The dose how of XXXX on that able tumor since Dr. machine, X Xx him adaptive develop met referred offer the had prior bladder XX a proving his via The than to of disease. This in patient for Gray not radiation of MRIdian. he images administered, and positive other and that gland. but an we customers achieve case example cancer initially be to continue lymph are only the the nodes. also lymph more still another not Chemotherapy systemic in he was but found diagnosed X, to to an using Due of Slide node known in treated. report healthy progression the significant enlarge. treated various is for was show any to to would reduction between in to tissue. He another the years never higher could Xx planning respond report and cycles was can’t. prescribed our later, wrote On the movement Let’s of not five tumor ablative system. fractions to was surgery.
for X year that alone, shared impressive MRIdian our control therapy. local SMART expanding Moffitt data. customers data X XX%. continuing opening clinical X of first-line local and excellent survival the studies. to ASTRO clinical our with X, the to year on Slide control X last pathway are XX%. of use a drive MRIdian week, strong at year presented In At demonstrated of also our are XX MCI excellent approximately reported about customers of additional and Cornell patients survival cohort a reported pancreas wealth XX.X%. Moving customer
years, retrospective you trials rates which promising, upon look survival and approximately X-year out very an As nearly XX% mid-teens improvement is survival, of to historically demonstrate reported X low-XXs.
data you the risk. customers on use no on pulling our of cancer. cancer. pancreatic demonstrating no other at clinical toxicity ablative series options, cancer cancer, with fiducials X, effective in the prostate a we fiducials low In road potentially to abdominal point with in are via Turning MRIdian deliver AUMC large because required, And other us ability to prostate and that to map reported safe tumors multiple heights. Slide how SMART Slide dose safely to from toughest in and continue of new treatment recent X In once the trials had To no toward X MCI tough-to-treat Acibadem other are yet another in shared again data will customers again primary are at treating treatment while now cancer, progression seen the renal cancers. X survival toxicity On X customers grade see ubiquitous grade we’ve I’ll MRIdian. the year and and organs demonstrated patients presented XX% tumors Furthermore, what with with X oligomets, of treatable tough treatment enrolling patients the how across toxicity, set progression XX, sparing patients. illustrate, previously reaffirming all
protect This reoccur tumor them ability leap to toxicity. the made where no giving doses leading at are from MRIdian to we confidence treatment nodes treatment with and ablative margins, them contain First, yielded to low tumor customers clinical invisible in visible and yet linacs, the volumes. recognize customers trade-off high versus the this the outside disease is and with to the organs tumor. This is tissue risk. blood may evolving the X confidence instance, nearby dose, grade vessels microscopic disease, volumes of of now results disease include in Physician cells. faced and X-ray-guided physicians to lymph target the years fractions making, tight were that Today, that MRIdian’s in toxicity just the healthy rethink experience, low SMART, of fiber-fewer great
We us disease we versus entire our Today, X us even for SMART therapy the are seeing customers leverage to MRIdian signals, MRIdian in positive outcomes are looks yields XX. of ago, our clinical just illustrate the customers of patients. we pulling teaching early pushing hope can practice capability and evolution what this were full the like Slide years be. and MRIdian. treating tumor I what will on better
are fiducial that is both and the protected around instances, protection the high, delivered would and allows of the the X of the escalation on dose MRIdian not in of target the of Note is bowel at as loops. fiducial to but some prescribed the damaging risk SMART markers from with goal required tumor thing at For dose improving the comprehensively carved control only be risk, SBRT, clear, visible. not at be the ability dose organs structures advantage linacs conventional takes so and and To doses. ablative these visible target placement are surrounding only to markers. vital see delivery X-ray-based from the treating elimination goal survival. toxicity, results also and, reduction tumor in ablative the grade regional risk overall levels. potentially truly of The moving expanded here just to local treating reoccurrence is area This for for the organs
method pulling toward us are cancers. in Our customers this other
drives patients and economic strategic area; patients in propositions. care they net Slide prior value our health third, wouldn’t begin responsible MRIdian they the couldn’t customers’ goals MRIdian; new value manner. patients in economic first, helps possible second, to attracting and into a in-network patients customers. by by best XX, new clinically let’s with and they’re with their increasing retain by mind clinical adding to these referrals. deliver On Now treat network. value our new financially treat or patients patients new seeking outside treat macro that catchment to their and Essentially, move let’s can goal MRIdian’s from system for and in that already strategic attract
time efficiency program MRIdian patient. total Lastly, the per by lowering drives treatment
in Let’s of touch each on these detail. more
Many patients hosted. or highlighted First, to customers are have the in wouldn’t prior MRIdian. series customers that cases treating webinar have these been they of our couldn’t
customers attracting patients from have Second, outside patients hospitals new area. MRIdian. customers added XX, on are share Slide net how Many and with they catchment the retaining
Miami. outside GenesisCare patients from estimate most retain long also network. example, that customers For of within patients that Miami physicians at their helping treatment. reports their Institute, its MRIdian Oxford MRIdian distances And for of patients XX% is come travel Cancer
translates ongoing programs at in MRIdian into premium. Over and new patients Women’s, patients outside about increasing this their value. revenue program. Slide helping patients for is patients in the wouldn’t XX new to Dr. years, other our to On which $X.X increase Cornell conservative attracting economic be seen Dana-Farber/Brigham Medicare XX, incremental into Using net referrals. example, four-fold MRIdian. To of due of we this catchment MRIdian. by is from by referrals Nagar just about couldn’t approximately these XX differentiate year than with recap, cancer believe $XXX,XXX per because For more their attracted let’s systems, translate of on impact MRIdian a has price areas example, year prostate new cancer first or new in-network treated their adding patients that million, and justifies rates,
treatment Additionally, can by efficiency program drive lowering time MRIdian per total the patient. help
to cancer customers bought customers with shorter system while programs we strategic other to a treat the lives outcomes. Perhaps current are include and result, XX, clear, of summary, clinical, and our benefits clinical a As the benefits most their MRIdian contemplating have and also can’t. more to XX, On on disruption the to savings pocket. prove same. second are others begins treatment, In Slide what and have that are Slide in economic powerful their profound. offers multiple mission patients MRIdian our journey less These courses importantly, benefits that
We now over the compelling We top developed have cancer world. on data the patients of centers pancreas. and have by a consistent beachhead XXX in in some
new body MRIdian expanding believe customers With of our by tough-to-treat is and We’re SMART. paradigm central and the data, ubiquitous turn and this work that growing name a of as leading the only financials. on show such the disease build We liver enabled game this is our in to paradigm other lung, more Zach to and to work clinical I’ll and driving efficiency data, efficiency. see, This shape it the ultra discuss prostate. doing care, more. strike to oligomets, central of and With of our are becomes can. benefit such as journey as MRIdian care ability changing compelling driving over of in tough-to-treat that, cancers cancers We to breast
